Compounds and compositions for ossification and methods related thereto
US-9511071-B2 · Dec 6, 2016 · US
US9808464B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9808464-B2 |
| Application number | US-201615334030-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 25, 2016 |
| Priority date | Aug 18, 2010 |
| Publication date | Nov 7, 2017 |
| Grant date | Nov 7, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.
Opening claim text (preview).
The invention claimed is: 1. A method of forming bone or cartilage, comprising implanting a graft composition comprising a 2,4-diamino-1,3,5-triazine derivative or salt thereof in a subject under conditions such that bone or cartilage forms in the graft composition, wherein the 2,4-diamino-1,3,5-triazine derivative has the following formula: or salts thereof, wherein if is a single bond then R 3 is alkyl, phenyl, benzyl, carbocyclyl, aryl, or heterocyclyl wherein R 3 is optionally substituted with one or more the same or different R 4 ; R 2 is hydrogen or alkyl; and R 1 is hydrogen or alkyl; or if is a double bond then R 2 and R 3 are absent; R 1 is alkyl, alkenyl, carbocyclyl, aryl, or heterocyclyl wherein R 3 is optionally substituted with one or more the same or different R 4 , R 4 is alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl) 2 amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R 4 is optionally substituted with one or more, the same or different, R 5 ; and R 5 is halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl, or heterocyclyl. 2. The method of claim 1 , wherein the graft composition further comprises a bone morphogenetic protein. 3. The method of claim 1 , wherein the subject has a void in the bony structure wherein the graft composition is implanted in the void. 4. The method of claim 3 , wherein the void is in a bone selected from an extremity, maxilla, mandible, pelvis, spine and/or cranium. 5. The method of claim 3 , wherein said void is a result of surgical removal of bone. 6. The method of claim 1 , further comprising the step of securing movement of bone structure with a fixation system, and removing the system after bone forms in the implanted graft. 7. The method of claim 1 , wherein the 2,4-diamino-1,3,5-triazine derivative is a compound selected from the group consisting of: 1-benzyl-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 1-(4-methoxyb enzyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 1-(3-methoxyb enzyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 1-(4-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 1-(3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 1-(3-chloro-4-methoxyphenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 1-(3-chloro-4-methylphenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 1-(4-bromo-2-fluorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 1-(2-bromo-4-methylphenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 6,6-dimethyl-1-(4-methyl-3-nitrophenyl)-1,6-dihydro-1,3,5-triazine-2,4-diamine; 1-(3-chloro-4-fluorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 1-(3-chloro-5-fluorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1((2H))-yl)phenol; 1-(2-chloro-5-methoxyphenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; and 1-(2-chloro-4-methyl phenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine or salts thereof. 8. A method of performing spinal fusion, comprising implanting a bone graft composition comprising a 2,4-diamino-1,3,5-triazine derivative or salt thereof configured to grow bone between two vertebrae of a subject, wherein the 2,4-diamino-1,3,5-triazine derivative has the following formula: or salts thereof, wherein if is a single bond then R 3 is alkyl, phenyl, benzyl, carbocyclyl, aryl, or heterocyclyl wherein R 3 is optionally substituted with one or more the same or different R 4 ; R 2 is hydrogen or alkyl; and R 1 is hydrogen or alkyl; or if is a double bond then R 2 and R 3 are absent; R 1 is alkyl, alkenyl, carbocyclyl, aryl, or heterocyclyl wherein R 3 is optionally substituted with one or more the same or different R 4 , R 4 is alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl) 2 amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R 4 is optionally substituted with one or more, the same or different, R 5 ; and R 5 is halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methyl sulfinyl, ethyl sulfinyl, mesyl, ethyl sulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl, or heterocyclyl. 9. The method of claim 8 , wherein the graft composition further comprises a bone morphogenetic protein. 10. The method of claim 8 , wherein the 2,4-diamino-1,3,5-triazine derivative is a compound selected from the group consisting of: 1-benzyl-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 1-(4-methoxybenzyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 1-(3- methoxybenzyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 1-(4-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 1-(3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 1-(3-chloro-4-methoxyphenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 1-(3-chloro-4-methylphenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 1-(4-bromo-2-fluorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 1-(2-bromo-4-methylphenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 6,6-dimethyl-1-(4-methyl-3-nitrophenyl)-1,6-dihydro-1,3,5-triazine-2,4-diamine; 1-(3-chloro-4-fluorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 1-(3-chloro-5-fluorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; 2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1((2H))-yl)phenol; 1-(2-chloro-5-methoxyphenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine; and 1-(2-chloro-4-methylphenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine or salts thereof. 11. A method of preventing or treating a bone fracture comprising administering a pharmaceutical composition comprising a 2,4-diamino-1,3,5-triazine derivative or pharmaceutically acceptable prodrug or salt thereof to a subject at risk for, exhibiting symptoms of, or diagnosed with a bone fracture, wherein the 2,4-diamino-1,3,5-triazine derivative has the following formula: or salts thereof, wherein if is
for bone diseases, e.g. rachitism, Paget's disease · CPC title
for reconstruction of bones; weight-bearing implants · CPC title
Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title
Tissue-regenerating or healing or proliferative agents · CPC title
Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.